MT reports honoraria from AstraZeneca, Daiichi-Sankyo, Eisai, Eli Lilly, MSD, and Pfizer Inc. KI reports institutional support from MSD, Daiichi-Sankyo, Chugai, AstraZeneca, Sanofi, Astellas, Ono, Takeda, Eisai, Gilead, and Novartis. MK reports honoraria from Guardant Health, Chugai, Daiichi-Sankyo, Pfizer Inc, and Eisai; and institutional support from Nippon Kayaku, Kyowa Kirin, Guardant Health, Shimadzu, GL Sciences; and clinical trial investigator support from JBCRG, Roche, Eli Lilly, MSD, and Chugai. YS reports honoraria from Pfizer Inc, Daiichi-Sankyo, Eli Lilly, MSD, AstraZeneca, Eisai, Chugai, and Nippon Kayaku. KY reports honoraria from Pfizer Inc, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, PDR Pharma, MSD, Boeringer Ingelheim, Ono, Daiichi-Sankyo, Bayer, Jansen, Asteras, Bristol Myers Squibb, Novartis, Sanofi, and Merk Biopharma; institutional support from MSD, Daiichi-Sankyo, Merk Biopharma, AstraZeneca, Taiho, Pfizer Inc, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boeringer Ingelheim, Kyowa Kirin, Nihon Kayaku, and Haihe; clinical investigator support from MSD, Daiichi-Sankyo, Genmab, Seagen, AstraZeneca, Taiho, Merk Biopharma Pfizer Inc, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boeringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, and Haihe; and has participated on advisory boards for Eisai, Astra Zeneca, Sanofi, Genmab, Gliad, OncXerna, Takeda, Novartis, MSD, and Henlius. MH reports honoraria from Daiichi-Sankyo, MSD, and Eli Lilly; and research funds from Konika Minolta REALM. NY reports research funding from AstraZeneca and Pfizer Inc. YM and AM are employees of and stockholders in Pfizer Inc. NM reports honoraria from Chugai, Pfizer Inc, AstraZeneca, Eli Lilly, and Daiichi-Sankyo; and institutional support from Chugai, Eli Lilly, AstraZeneca, Pfizer Inc, Daiichi-Sankyo, MSD, Eisai, Novartis, Sanofi, Kyowa Kirin, and Nippon Kayaku. HY, TO, MI and HM have no disclosures.